In Vitro Diagnostics (IVD) include reagents, instruments, and systems intended for use in the diagnosis of disease or other conditions, including the determination of the state of health, in order to treat or prevent disease. The reagents, instruments and systems are used in the collection, preparation, and examination of specimens taken from the human body. This includes Cardiac Disease, Hematological Disorders, Hormonal Disorders, Metabolic Disorder, Infectious Disease, IVD Analyzers, Oncology and Reproductive Health Diagnostics. Chlamydia trachomatis Tests are carried out to diagnose infections, which can result in trachoma, lymphogranuloma venereum, nongonococcal urethritis, cervicitis, salpingitis, pelvic inflammatory disease. Neisseria gonorrhoeae Tests are carried out to diagnose the sexually transmitted genitourinary infection gonorrhoea. GlobalData uses proprietary data and analytics to provide a comprehensive report on the chlamydia trachomatis and neisseria gonorrhoeae tests market in the US. Buy the latest report here.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

In 2023, GlobalData’s Market Model methodology determined that the leading player in the chlamydia trachomatis and neisseria gonorrhoeae tests market in the US was Becton Dickinson and Co followed by Hologic, Thermo Fisher Scientific, Quidelortho, ZeptoMetrix, Danaher, F. Hoffmann-La Roche, Bio-Rad Laboratories, Abbott Laboratories and Trinity Biotech.

Understanding market size can be crucial to evaluate opportunities and make informed decisions about market entry and exit. Medical device companies can identify attractive segments in respective markets as well as develop marketing strategies based on forecasts for those segments.

Chlamydia trachomatis and Neisseria gonorrhoeae Tests include the sub-segments Neisseria gonorrhoeae Nucleic Acid Amplification Tests (NAATs), Dual CT/NG Nucleic Acid Amplification Tests (NAATs), Chlamydia trachomatis Nucleic Acid Amplification Tests (NAATs), Other tests for Chlamydia trachomatis include Direct Fluorescent Antibody (DFA), Indirect Fluorescent Antibody (IFA), Immunochromatography, and Enzyme-Linked Immunosorbent Assay (ELISA) and, Other Neisseria gonorrhoeae Tests encompass DFA, IFA, Immunochromatography, Cell Culture, and Point of Care devices.

See Also:

The chlamydia trachomatis and neisseria gonorrhoeae tests market in the US can expand or contract due to a variety of reasons including population demographics, disease incidence and prevalence, macroeconomic issues, and geopolitical considerations. Disruption to a market could be caused by a sudden, unexpected change in these factors, but it could also be driven by changes in clinical practice, leading to a change in diagnosis or treatment of patients, as part of a process to generally improve medical practice.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

For the latest analysis of the market size chlamydia trachomatis and neisseria gonorrhoeae tests in the US, buy the report here.